Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2000 2
2001 2
2002 1
2003 2
2005 1
2006 2
2008 2
2009 2
2011 2
2012 4
2013 1
2014 3
2015 1
2017 2
2018 2
2019 1
2020 2
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Facial muscle hypertrophy"
Page 1
Temporalis muscle hypertrophy and reduced skull eccentricity in Duchenne muscular dystrophy.
Straathof CS, Doorenweerd N, Wokke BH, Dumas EM, van den Bergen JC, van Buchem MA, Hendriksen JG, Verschuuren JJ, Kan HE. Straathof CS, et al. J Child Neurol. 2014 Oct;29(10):1344-8. doi: 10.1177/0883073813518106. Epub 2014 Mar 19. J Child Neurol. 2014. PMID: 24646504
Muscle hypertrophy and muscle weakness are well known in Duchenne muscular dystrophy. ...Hypertrophy of the temporal muscles and changes in skull eccentricity appear to occur early in the course of Duchenne muscular dystrophy. ...
Muscle hypertrophy and muscle weakness are well known in Duchenne muscular dystrophy. ...Hypertrophy of the temp …
Somatic GNAQ mutation in different structures of port-wine macrocheilia.
Ma G, Yu Z, Liu F, Wang L, Yu W, Zhu J, Gu H, Liu Y, Cai R, Lin X. Ma G, et al. Br J Dermatol. 2018 Nov;179(5):1109-1114. doi: 10.1111/bjd.16830. Epub 2018 Aug 14. Br J Dermatol. 2018. PMID: 29878304

RESULTS: The GNAQ R183Q mutation was not detected in gland samples but was found in 90%, 95% and 95% of the skin, mucosal and muscle samples, respectively. The lowest levels of mutations were found in the glands (P < 0.001 vs. skin, mucosa and muscle), and levels

…
RESULTS: The GNAQ R183Q mutation was not detected in gland samples but was found in 90%, 95% and 95% of the skin, mucosal and muscle …
Muscular and functional changes following adenotonsillectomy in children.
Bueno Dde A, Grechi TH, Trawitzki LV, Anselmo-Lima WT, Felício CM, Valera FC. Bueno Dde A, et al. Int J Pediatr Otorhinolaryngol. 2015 Apr;79(4):537-40. doi: 10.1016/j.ijporl.2015.01.024. Epub 2015 Jan 28. Int J Pediatr Otorhinolaryngol. 2015. PMID: 25669724
BACKGROUND: It is recognized that adenotonsillar hypertrophy leads to muscular and functional changes in face, and that adenotonsillectomy is associated to improvement in this condition. ...We conclude that waiting for a spontaneous muscular and functional facial re …
BACKGROUND: It is recognized that adenotonsillar hypertrophy leads to muscular and functional changes in face, and that adenotonsille …
Assessment of Electromyographic Changes in a Patient with Masseter Hypertrophy and Muscle Pain after Botulinum Injections: A Case Report and 5 Months Follow-up.
Bianco E, Tagliabue R, Mirabelli L, Maddalone M. Bianco E, et al. J Contemp Dent Pract. 2022 Feb 1;23(2):226-231. J Contemp Dent Pract. 2022. PMID: 35748454
It presents as a symmetrical or asymmetrical increase in the masseter muscle. Masseter muscle hypertrophy (MMH) sometimes can be related to bruxism symptoms like muscle and/or temporomandibular joint (TMJ) pain. ...She also complained about esthetics b …
It presents as a symmetrical or asymmetrical increase in the masseter muscle. Masseter muscle hypertrophy (MMH) sometim …
Temporal volume increase after reduction of masseteric hypertrophy utilizing incobotulinumtoxin type A.
Nikolis A, Enright KM, Rudolph C, Cotofana S. Nikolis A, et al. J Cosmet Dermatol. 2020 Jun;19(6):1294-1300. doi: 10.1111/jocd.13434. Epub 2020 Apr 27. J Cosmet Dermatol. 2020. PMID: 32338450 Free PMC article.
BACKGROUND: Treating the lower face with neuromodulators and targeting the masseter muscle can reduce masseteric hypertrophy but can also change the facial shape. A novel observation after the treatment of the masseter muscle with incobotulinumtoxin Ty …
BACKGROUND: Treating the lower face with neuromodulators and targeting the masseter muscle can reduce masseteric hypertrophy b …
Niemann-Pick type A disease with new mutation: a case report.
Aghamahdi F, Nirouei M, Savad S. Aghamahdi F, et al. J Med Case Rep. 2022 Jul 27;16(1):288. doi: 10.1186/s13256-022-03486-5. J Med Case Rep. 2022. PMID: 35883096 Free PMC article.
Type A is a rare, untreatable disease with early manifestations and a poor prognosis, with newborns rarely surviving for 2-3 years. CASE PRESENTATION: A 1-year-old Persian boy was referred to our clinic due to abdominal distention and poor weight gain. ...The initial diagn …
Type A is a rare, untreatable disease with early manifestations and a poor prognosis, with newborns rarely surviving for 2-3 years. C …
Botulinum toxin type A treatment for contouring of the lower face.
Park MY, Ahn KY, Jung DS. Park MY, et al. Dermatol Surg. 2003 May;29(5):477-83; discussion 483. doi: 10.1046/j.1524-4725.2003.29116.x. Dermatol Surg. 2003. PMID: 12752514
BACKGROUND: Since type A botulinum toxin was first reported for the treatment of masseter muscle hypertrophy in 1994, there have been few reports about cosmetic indications for contouring procedures of the lower face with injection of botulinum toxin type A, and thi …
BACKGROUND: Since type A botulinum toxin was first reported for the treatment of masseter muscle hypertrophy in 1994, there ha …
A review of the current uses of Botox for dentally-related procedures.
Bhogal PS, Hutton A, Monaghan A. Bhogal PS, et al. Dent Update. 2006 Apr;33(3):165-8. doi: 10.12968/denu.2006.33.3.165. Dent Update. 2006. PMID: 16700273 Review.
This drug has received wide coverage in the press and media for its cosmetic advantages, especially in the facial region. The clinician may be aware of the many courses becoming available and aimed at dentists to start using it in the cosmetic context. ...
This drug has received wide coverage in the press and media for its cosmetic advantages, especially in the facial region. The clinici …
Management of bilateral masseter muscle hypertrophy.
Özkan BT, Tabrizi R, Cigerim L. Özkan BT, et al. J Craniofac Surg. 2012 Jan;23(1):e14-6. doi: 10.1097/SCS.0b013e31824207a2. J Craniofac Surg. 2012. PMID: 22337448
Masseter muscle hypertrophy is characterized by unilateral or bilateral enlargement of the masseter muscles affecting both females and males after puberty. Limitations on mouth opening, swollen cheek, and also tension in the region of the hypertrophied …
Masseter muscle hypertrophy is characterized by unilateral or bilateral enlargement of the masseter muscles affecting b …
Complications of botulinum toxin injection for masseter hypertrophy: Incidence rate from 2036 treatments and summary of causes and preventions.
Peng HP, Peng JH. Peng HP, et al. J Cosmet Dermatol. 2018 Feb;17(1):33-38. doi: 10.1111/jocd.12473. Epub 2017 Dec 18. J Cosmet Dermatol. 2018. PMID: 29250900
BACKGROUND: Masseter hypertrophy is a common, prominent feature in many Asian patients, and correction procedures are often requested for esthetic reasons. ...METHODS: Six hundred and eighty patients received a total of 2036 sessions of toxin injection for masseter hype …
BACKGROUND: Masseter hypertrophy is a common, prominent feature in many Asian patients, and correction procedures are often requested …
35 results